Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Inks Sequencing Partnerships With Qiagen, Illumina

NEW YORK (GenomeWeb) – 10x Genomics has announced two new sequencing partnerships with Qiagen and Illumina.

Yesterday, 10x said that it is partnering with Qiagen to co-develop and co-market next-generation sequencing and single-cell biology analysis workflows and informatics solutions.

Under the terms of the agreement, Qiagen will optimize its sample technologies — including its MagAttract HMW DNA kit — for use on 10x's GemCode platform and Chromium product suite for single-cell analysis.

They also plan to develop solutions that support complete single-cell biology workflows by combining 10x's GemCode technology with Qiagen's single-cell biology portfolio and QIAseq NGS solutions, and to investigate the implementation of GemCode with Qiagen's GeneReader NGS system.

"We welcome the opportunity to partner with Qiagen, with their comprehensive offerings for genomic analysis, ranging from sample preparation technologies to bioinformatics solutions for the interpretation and analysis of genomic data," said 10x CEO Serge Saxonov in a statement. "Access to long-range sequence information is becoming the standard for obtaining the most comprehensive understanding of disease, and we expect this collaboration to allow our respective customers to gain valuable insights that have previously not been possible."

The companies will co-market the 10x Chromium products and the Qiagen sample handling and prep technologies, and plan to collaborate to develop a comprehensive portfolio of products to improve sample preparation, sequencing, and single-cell biology, 10x said.

"This partnership will further the potential of each of our product lines while providing significant new capabilities to NGS researchers," added Qiagen CEO Peer Schatz in the statement.

Separately, 10x and Illumina said today that they are partnering to co-market Illumina's sequencing systems and 10x's linked-read sequencing products. 10x’s microfluidics-based molecular barcoding long read solutions, built on the GemCode platform, can be used with Illumina sequencers to give researchers a wider range of sequencing applications to choose from, the company said.

"We are excited to establish this ecosystem and to have 10x Genomics as a partner," Illumina Chief Commercial Officer Christian Henry said in a statement. "The GemCode technology provides HiSeq X, HiSeq, NextSeq, and MiSeq sequencing users a plug-and-play upgrade to their existing systems, giving them access to a broad range of critical information, and at a much lower cost and a higher quality than other long-read sequencing systems on the market." 

This is the second such partnership Illumina has announced in recent months. The company also signed a co-marketing agreement with ag-bio firm NRGene in January, and expects to announce more ecosystem partnerships in 2016.

Financial terms of the deals were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.